Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Atrasentan hydrochloride (ABT-627 hydrochloride) 是内皮素 A 受体选择性拮抗剂,抑制内皮素 A 受体活性的IC50为 0.0551 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 428 | 现货 | ||
2 mg | ¥ 617 | 现货 | ||
5 mg | ¥ 947 | 现货 | ||
10 mg | ¥ 1,390 | 现货 | ||
25 mg | ¥ 2,820 | 现货 | ||
50 mg | ¥ 3,970 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,190 | 现货 |
产品描述 | Atrasentan hydrochloride (ABT-627 hydrochloride) is an antagonist of the endothelin receptor(IC50 = 55.1 μM for ETA). |
靶点活性 | ETA:55.1 μM |
体外活性 | Atrasentan(0-50 μM)显著抑制LNCaP和C4-2b前列腺癌细胞生长。ABT-627与Taxotere联合使用,相比单独使用任一药物,可显著降低前列腺癌活细胞的数量,并更大程度地下调NF-κB DNA结合活性[2]。Atrasentan显著诱导多种CYPs和药物转运体的表达。它是一种中等强度的P-gp抑制剂(IC50:15.1 μM,在P388/dx细胞中)和一种弱BCRP抑制剂(IC50:59.8 μM,在MDCKII-BCRP细胞中)[3]。 |
体内活性 | Atrasentan(3 mg/kg, p.o.)通过抑制大型内皮素-1(1 nmol/kg)诱导的加压反应,在去髓大鼠中显示出效果[1]。此外,Atrasentan(10 mg/kg, i.p.)在SCID-hu模型中对C4-2b肿瘤在骨环境中的生长有一定程度的抑制作用[2]。 |
激酶实验 | Cells are incubated and treated with Atrasentan. They are then washed twice with PBS and lysed in ice-cold lysis buffer [20 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium PPi, 1 mM β-glycerophosphate, 1 mM sodium orthovanadate, 1 μg/mL leupeptin, and 1 mM PMSF]. The extracts are centrifuged to remove cellular debris, and the protein content of the supernatants is determined using the bicinchoninic acid (BCA) protein assay reagent. Proteins (150 μg) are incubated with gentle rocking at 4°C overnight with immobilized Akt antibody cross-linked to agarose hydrazide beads. After the Akt is selectively immunoprecipitated from the cell lysates, the immunoprecipitated products are washed twice with lysis buffer and twice with kinase assay buffer [25 mM Tris (pH 7.5), 10 mM MgCl2, 5 mM β-glycerol phosphate, 0.1 mM sodium orthovanadate, 2 mM DTT] and then resuspended in 40 μL of kinase assay buffer containing 200 μM ATP and 1 μg GSK-3α/β fusion protein. The kinase assay reaction is allowed to proceed at 30°C for 30 min and stopped by the addition of Lamelli SDS sample buffer. Reaction products are resolved by 10% SDS-PAGE, followed by Western blotting with antiphosphorylated GSK-3α/β antibody. For analysis of the total amount of Akt, 40 μg of protein from the lysate samples are resolved by 10% SDS-PAGE, followed by Western blotting with anti-Akt antibody [2]. |
细胞实验 | All three prostate cancer cell lines (LNCaP, C4-2b, and PC-3 cells) are seeded at a density of 3 × 10^3 cells per well in 96-well microtiter culture plates. After overnight incubation, the medium is removed and replaced with a fresh medium containing different concentrations of ABT-627 (0-50 μM) diluted from a 10-mM stock. After 72 h of incubation with the drug, 20 μL of MTT solution (5 mg/mL in PBS) is added to each well and incubated further for 2 h. Upon termination, the supernatant is aspirated and the MTT formazan formed by metabolically viable cells is dissolved in isopropanol (100 μL). The plates are mixed for 30 min on a gyratory shaker, and the absorbance is measured at 595 nm on a plate reader [2]. |
动物实验 | YM598 (0.3, 1, and 3 mg/kg), atrasentan (0.3, 1, and 3 mg/kg), or 0.5% methylcellulose as vehicle is orally administered to rats with a dosing cannula. The dosing volume of the test substances and vehicle is set at 5 mL/kg. Approximately 20 min after administration of compounds, the rats are anesthetized with sodium pentobarbital, and then pithed and ventilated 30 min after dosing. Approximately 1 h after oral administration of compounds, big endothelin-1 (1 nmol/kg) is intravenously administered, and blood pressure is measured. In these two experiments, the dose of test compound that causes 50% inhibition (ID50) of the big endothelin-1-induced increase in diastolic blood pressure is determined by linear regression analysis [1]. |
别名 | (+)-A 127722 hydrochloride, ABT-627 hydrochloride, 盐酸阿曲生坦, A-147627 hydrochloride |
分子量 | 547.08 |
分子式 | C29H39ClN2O6 |
CAS No. | 195733-43-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 0.4 mg/mL (0.73 mM), when pH is adjusted to 4 with HCl. Sonication and heating to 60℃ are recommended.
DMSO: 30 mg/mL (54.84 mM)
0.1 M HCL: < 1 mg/mL (insoluble), when pH is adjusted to 1 with HCl. Sonication and heating to 60℃ are recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8279 mL | 9.1394 mL | 18.2789 mL | 45.6972 mL |
5 mM | 0.3656 mL | 1.8279 mL | 3.6558 mL | 9.1394 mL | |
10 mM | 0.1828 mL | 0.9139 mL | 1.8279 mL | 4.5697 mL | |
20 mM | 0.0914 mL | 0.457 mL | 0.9139 mL | 2.2849 mL | |
50 mM | 0.0366 mL | 0.1828 mL | 0.3656 mL | 0.9139 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Atrasentan hydrochloride 195733-43-8 GPCR/G Protein Endothelin Receptor ABT-627 Hydrochloride (+)-A 127722 hydrochloride A 147627 A-147627 ABT-627 hydrochloride (+)-A 127722 A147627 Hydrochloride Atrasentan 盐酸阿曲生坦 A 147627 Hydrochloride ABT 627 Hydrochloride ABT627 Atrasentan Hydrochloride ABT-627 ABT 627 A-147627 Hydrochloride Inhibitor A-147627 hydrochloride A-127722 Hydrochloride ABT627 Hydrochloride A127722 Hydrochloride A 127722 Hydrochloride inhibit A147627 inhibitor